Repeated treatment with alpha 7 nicotinic acetylcholine receptor ligands enhances cognitive processes and stimulates Erk1/2 and Arc genes in rats.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 8004872 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7549 (Electronic) Linking ISSN: 01664328 NLM ISO Abbreviation: Behav Brain Res Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
    • Subject Terms:
      Behavior, Animal/*drug effects ; Cytoskeletal Proteins/*drug effects ; Extracellular Signal-Regulated MAP Kinases/*drug effects ; Hippocampus/*drug effects ; Nerve Tissue Proteins/*drug effects ; Nicotinic Agonists/*pharmacology ; Nootropic Agents/*pharmacology ; Prefrontal Cortex/*drug effects ; Recognition, Psychology/*drug effects ; alpha7 Nicotinic Acetylcholine Receptor/*drug effects; Animals ; Male ; Nicotinic Agonists/administration & dosage ; Nootropic Agents/administration & dosage ; RNA, Messenger/drug effects ; Rats ; Rats, Sprague-Dawley
    • Abstract:
      The α7 nicotinic acetylcholine receptor (α7 nAChR) is a potential target for the treatment of cognitive decline in patients with schizophrenia, Alzheimer's disease, and attention-deficit/hyperactivity disorder. Here we examined the promnesic activity of the α7 nAChR agonist (A582941), the type I (CCMI), and the type II (PNU120596) positive allosteric modulators (PAMs) in rats following single and repeated (once daily for seven days) treatment. To determine the neuronal mechanisms underlying the procognitive activity of the tested compounds, levels of the extracellular signal-regulated kinases (Erk1/2) and the activity-regulated cytoskeleton-associated protein (Arc) mRNAs were assessed in the frontal cortical and hippocampal brain regions. Using the novel object recognition test, we demonstrate that the lower doses of A582941 (0.1 mg/kg), CCMI (1 mg/kg), and PNU120596 (0.3 mg/kg) improved recognition memory after repeated but not single administration, suggesting a cumulative effect of repeated dosing. In contrast, the higher doses of A582941 (0.3 mg/kg), CCMI (3 mg/kg) and PNU120596 (1 mg/kg) demonstrated promnesic efficacy following both single and repeated administration. Subsequent in situ hybridization revealed that repeated treatment with A582941 and CCMI, but not PNU120596 enhanced mRNA expression of the Erk1/2 and Arc in the frontal cortex and hippocampus. Present data suggest that both the α7 nAChR agonist and PAMs exhibit procognitive effects after single and repeated administration. The increased level of the Erk1/2 and Arc genes is likely to be at least partially involved in this effect.
      (Copyright © 2021 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Alpha 7 nicotinic receptor; Arc; Cognition; Erk1/2; Memory; Positive allosteric modulator
    • Accession Number:
      0 (Cytoskeletal Proteins)
      0 (Nerve Tissue Proteins)
      0 (Nicotinic Agonists)
      0 (Nootropic Agents)
      0 (RNA, Messenger)
      0 (activity regulated cytoskeletal-associated protein)
      0 (alpha7 Nicotinic Acetylcholine Receptor)
      EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
    • Publication Date:
      Date Created: 20210503 Date Completed: 20220127 Latest Revision: 20220127
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.bbr.2021.113338
    • Accession Number:
      33940049